熱門資訊> 正文
ALX肿瘤学GAAP每股收益为-0.76美元在线
2024-08-09 15:06
- ALX Oncology press release (NASDAQ:ALXO): Q2 GAAP EPS of -$0.76 in-line.
- Cash, cash equivalents and investments as of June 30, 2024, were $186.2 million.
- The company believes its cash, cash equivalents and investments, which includes the proceeds from sales under its at-the-market offering in the first half of 2024 are sufficient to fund planned operations well into Q1 2026.
More on ALX Oncology
- ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation
- ALX Oncology reports Phase 2 data for gastric cancer drug evorpacept
- Seeking Alpha’s Quant Rating on ALX Oncology
- Historical earnings data for ALX Oncology
- Financial information for ALX Oncology
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
